Log In
Print
BCIQ
Print
Print this Print this
 

Sabutoclax (ONT-701)

  Manage Alerts
Collapse Summary General Information
Company Oncothyreon Inc.
DescriptionSmall molecule pan-inhibitor of B cell lymphoma 2 (BCL-2; BCL2) proteins
Molecular Target B cell lymphoma 2 (BCL-2) (BCL2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today